Cell Therapy with Human Renal Cell Cultures Containing Erythropoietin-Positive Cells Improves Chronic Kidney Injury

Abstract

16-fold). hPKC(F؉) also significantly reduced levels of renal cortical monocyte chemotactic protein 1 (1.8-fold) and oxidative DNA marker 8-hydroxy-deoxyguanosine (8-OHdG) (2.4-fold). After 12 weeks, we detected few injected cells, which were localized mostly to the cortical interstitium. Although cell therapy with either hPKC(F؉) or hPKC improved renal function, the hPKC(F؉) subpopulation provides greater renoprotection, perhaps through attenuation of inflammation and oxidative stress. We conclude that hPKC(F؉) may be used as components of cell-based therapies for degenerative kidney diseases. STEM CELLS TRANSLATIONAL MEDICINE 2012;1: 373-383

Therapeutic use of human renal progenitor cells for kidney regeneration

“…Many results were 18 obtained from an extensive gene-expression profile analysis in Wilm's tumour, as this 19 paediatric tumour is characterized by loss of terminal progenitor differentiation 17 . The 20 population expressing foetal renal progenitor markers Six2, Wt1, Cited1, and Sall1 was shown 21 to co-express NCAM and FZD7 18 .…”

Human CD133+ Renal Progenitor Cells Induce Erythropoietin Production and Limit Fibrosis After Acute Tubular Injury

“…An effect on the reduction of early tissue fibrosis (up to day 14) was also shown using CD133 + embryonic renal cells29. In addition, adult mature renal cells and EPO-releasing fibroblasts have been proven to ameliorate renal function in models of chronic renal damage2425. In the present study, we investigated the effect of CD133 + cells during resolution of AKI, focusing not only on markers of renal injury, but also on molecular alterations involved in the persistence of damage as well as on maladaptive repair, leading to fibrosis and possibly to chronic injury.…”

“…The administration of recombinant EPO in experimental models of AKI and renal transplant promoted tubular cell survival and tissue vascularization, resulting in improved renal function1415161718192021 and long term reduction of fibrosis2223. EPO-releasing cells of fibroblastic origin have also been proven to be of protection in models of renal injury2425. The role of cell therapy on endogenous EPO production however has not been investigated yet.…”

Kidney diseases and tissue engineering

“…In particular, several reports focused on a cell population of EPO-positive renal cells. EPO, a cytokine produced by fibroblast-like cells in the kidney [82,83], has recently emerged as a renoprotective factor with anti-inflammatory and antioxidant activity. Our group developed a cell purification method to enrich the EPO-positive renal cell population [83].…”

“…EPO, a cytokine produced by fibroblast-like cells in the kidney [82,83], has recently emerged as a renoprotective factor with anti-inflammatory and antioxidant activity. Our group developed a cell purification method to enrich the EPO-positive renal cell population [83]. The results showed that intrarenal delivery of an EPO positive-enriched cell population facilitated more beneficial effects in treatment of renal injury, inflammation, and oxidative stress compared to unsorted cell cultures in a chronic kidney injury model, demonstrating that EPO-positive cells from primary renal cells can be considered as potential cell population for degenerative kidney diseases.…”